NCT01326468 2025-09-25
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase NA Withdrawn
Clinical Trials
9 trialsNCT01182883 2017-07-02
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00788580 2015-03-06
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00949026 2013-11-21
Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
Emory University
Phase 1 Withdrawn
NCT01281943 2013-07-04
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01781442 2013-05-01
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
Pfizer
Withdrawn
NCT01170052 2011-03-16
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Charite University, Berlin, Germany
Phase 1/2 Withdrawn